| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| HIV Infections | 33 | 2018 | 395 | 5.400 |
Why?
|
| Infectious Disease Transmission, Vertical | 19 | 2014 | 24 | 3.470 |
Why?
|
| Pregnancy Complications, Infectious | 14 | 2013 | 32 | 2.750 |
Why?
|
| Health Knowledge, Attitudes, Practice | 10 | 2022 | 357 | 2.750 |
Why?
|
| Papillomavirus Infections | 5 | 2022 | 67 | 2.440 |
Why?
|
| Humans | 145 | 2022 | 32082 | 2.080 |
Why?
|
| Staphylococcal Infections | 6 | 2015 | 77 | 2.050 |
Why?
|
| Sarcoidosis | 13 | 2012 | 28 | 2.030 |
Why?
|
| India | 17 | 2020 | 61 | 2.030 |
Why?
|
| Anti-Bacterial Agents | 17 | 2020 | 322 | 2.010 |
Why?
|
| Papillomavirus Vaccines | 4 | 2022 | 44 | 1.990 |
Why?
|
| Students, Medical | 3 | 2020 | 130 | 1.850 |
Why?
|
| Child | 53 | 2018 | 2439 | 1.810 |
Why?
|
| Female | 94 | 2022 | 19999 | 1.810 |
Why?
|
| Breast Feeding | 14 | 2014 | 43 | 1.770 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 5 | 2015 | 33 | 1.710 |
Why?
|
| Cross-Sectional Studies | 21 | 2022 | 1542 | 1.690 |
Why?
|
| Patient Acceptance of Health Care | 4 | 2022 | 172 | 1.650 |
Why?
|
| Anti-HIV Agents | 12 | 2014 | 55 | 1.610 |
Why?
|
| Uterine Cervical Neoplasms | 4 | 2022 | 36 | 1.580 |
Why?
|
| Infant | 39 | 2016 | 1061 | 1.560 |
Why?
|
| Adolescent | 41 | 2021 | 3568 | 1.540 |
Why?
|
| Male | 72 | 2021 | 19202 | 1.510 |
Why?
|
| Child, Preschool | 31 | 2017 | 1267 | 1.390 |
Why?
|
| Infant, Newborn | 22 | 2016 | 673 | 1.180 |
Why?
|
| Adult | 37 | 2020 | 9375 | 1.120 |
Why?
|
| Fever | 5 | 2015 | 60 | 1.110 |
Why?
|
| Influenza, Human | 4 | 2012 | 122 | 1.020 |
Why?
|
| HIV-1 | 10 | 2014 | 45 | 1.020 |
Why?
|
| Condylomata Acuminata | 2 | 2022 | 7 | 0.970 |
Why?
|
| Community-Acquired Infections | 5 | 2015 | 32 | 0.950 |
Why?
|
| Pregnancy | 22 | 2014 | 996 | 0.950 |
Why?
|
| Depression, Postpartum | 4 | 2014 | 9 | 0.950 |
Why?
|
| Diagnosis, Differential | 18 | 2015 | 516 | 0.930 |
Why?
|
| Rural Population | 3 | 2020 | 277 | 0.910 |
Why?
|
| Quality of Life | 4 | 2020 | 946 | 0.900 |
Why?
|
| Papillomaviridae | 3 | 2018 | 22 | 0.880 |
Why?
|
| Osteomyelitis | 3 | 2013 | 22 | 0.870 |
Why?
|
| Influenza A Virus, H1N1 Subtype | 3 | 2012 | 47 | 0.850 |
Why?
|
| Vaccination | 3 | 2022 | 138 | 0.850 |
Why?
|
| Nevirapine | 6 | 2014 | 6 | 0.850 |
Why?
|
| Zimbabwe | 19 | 2014 | 22 | 0.840 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 3 | 2009 | 44 | 0.830 |
Why?
|
| Antiviral Agents | 6 | 2012 | 108 | 0.820 |
Why?
|
| Foster Home Care | 2 | 2017 | 3 | 0.820 |
Why?
|
| Health Services Accessibility | 4 | 2013 | 242 | 0.810 |
Why?
|
| Arthritis, Infectious | 3 | 2013 | 24 | 0.810 |
Why?
|
| Immunocompromised Host | 3 | 2019 | 51 | 0.800 |
Why?
|
| Women's Health | 3 | 2020 | 235 | 0.790 |
Why?
|
| Epiglottitis | 1 | 2021 | 2 | 0.770 |
Why?
|
| Pediatrics | 3 | 2021 | 155 | 0.770 |
Why?
|
| Milk, Human | 6 | 2013 | 16 | 0.770 |
Why?
|
| Microcephaly | 2 | 2017 | 3 | 0.760 |
Why?
|
| Tomography, X-Ray Computed | 10 | 2021 | 917 | 0.760 |
Why?
|
| Marijuana Smoking | 1 | 2021 | 39 | 0.740 |
Why?
|
| Mucocutaneous Lymph Node Syndrome | 3 | 2009 | 9 | 0.730 |
Why?
|
| Mass Screening | 3 | 2009 | 263 | 0.730 |
Why?
|
| Biofuels | 1 | 2020 | 1 | 0.720 |
Why?
|
| Hepatitis B, Chronic | 1 | 2020 | 7 | 0.720 |
Why?
|
| Air Pollution, Indoor | 1 | 2020 | 10 | 0.710 |
Why?
|
| Self Disclosure | 1 | 2020 | 22 | 0.710 |
Why?
|
| Vincristine | 2 | 2019 | 17 | 0.710 |
Why?
|
| Drug Prescriptions | 1 | 2020 | 54 | 0.700 |
Why?
|
| Sepsis | 2 | 2015 | 161 | 0.670 |
Why?
|
| Attitude of Health Personnel | 2 | 2020 | 184 | 0.670 |
Why?
|
| Middle Aged | 16 | 2020 | 11834 | 0.670 |
Why?
|
| Sarcoma, Kaposi | 1 | 2019 | 8 | 0.660 |
Why?
|
| Students, Dental | 1 | 2019 | 2 | 0.660 |
Why?
|
| Pneumonia, Pneumocystis | 1 | 2019 | 6 | 0.660 |
Why?
|
| Pneumocystis carinii | 1 | 2019 | 6 | 0.660 |
Why?
|
| Students, Nursing | 1 | 2019 | 7 | 0.660 |
Why?
|
| Hemangioendothelioma | 1 | 2019 | 10 | 0.660 |
Why?
|
| Burns | 2 | 2021 | 100 | 0.660 |
Why?
|
| Drug Resistance, Bacterial | 3 | 2020 | 47 | 0.660 |
Why?
|
| Sirolimus | 1 | 2019 | 33 | 0.650 |
Why?
|
| Delayed Diagnosis | 1 | 2018 | 15 | 0.640 |
Why?
|
| Anti-Retroviral Agents | 1 | 2018 | 21 | 0.640 |
Why?
|
| Anxiety | 1 | 2020 | 191 | 0.630 |
Why?
|
| Young Adult | 15 | 2020 | 2665 | 0.620 |
Why?
|
| Health Status | 2 | 2020 | 400 | 0.610 |
Why?
|
| Prenatal Care | 3 | 2007 | 51 | 0.600 |
Why?
|
| Bacteremia | 3 | 2013 | 65 | 0.600 |
Why?
|
| Echinococcus | 1 | 2017 | 1 | 0.590 |
Why?
|
| Echinococcosis | 1 | 2017 | 2 | 0.590 |
Why?
|
| Early Detection of Cancer | 2 | 2016 | 93 | 0.580 |
Why?
|
| Exanthema | 3 | 2013 | 21 | 0.570 |
Why?
|
| Abscess | 3 | 2015 | 26 | 0.570 |
Why?
|
| Disease Outbreaks | 1 | 2017 | 43 | 0.570 |
Why?
|
| Cervical Intraepithelial Neoplasia | 1 | 2016 | 4 | 0.560 |
Why?
|
| Spleen | 1 | 2017 | 87 | 0.560 |
Why?
|
| Streptococcus pyogenes | 2 | 2010 | 16 | 0.550 |
Why?
|
| Ciprofloxacin | 2 | 2015 | 12 | 0.550 |
Why?
|
| Depression | 1 | 2020 | 445 | 0.550 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2018 | 154 | 0.550 |
Why?
|
| Maternal-Child Health Centers | 2 | 2013 | 4 | 0.550 |
Why?
|
| Head and Neck Neoplasms | 1 | 2018 | 130 | 0.550 |
Why?
|
| Urinary Tract Infections | 2 | 2015 | 45 | 0.550 |
Why?
|
| Urban Population | 3 | 2020 | 89 | 0.540 |
Why?
|
| Public Health | 1 | 2017 | 89 | 0.540 |
Why?
|
| Child Welfare | 1 | 2016 | 21 | 0.530 |
Why?
|
| Chromobacterium | 1 | 2015 | 1 | 0.520 |
Why?
|
| Imipenem | 1 | 2015 | 3 | 0.520 |
Why?
|
| Shock, Septic | 1 | 2015 | 25 | 0.520 |
Why?
|
| CD4 Lymphocyte Count | 6 | 2018 | 32 | 0.510 |
Why?
|
| Abdominal Abscess | 1 | 2015 | 5 | 0.510 |
Why?
|
| Follow-Up Studies | 8 | 2019 | 2263 | 0.510 |
Why?
|
| Frontal Sinusitis | 1 | 2015 | 4 | 0.510 |
Why?
|
| Epidural Abscess | 1 | 2015 | 5 | 0.510 |
Why?
|
| Guanidines | 2 | 2012 | 6 | 0.500 |
Why?
|
| Patient Compliance | 1 | 2017 | 225 | 0.500 |
Why?
|
| Cyclopentanes | 2 | 2012 | 16 | 0.500 |
Why?
|
| Physicians | 1 | 2017 | 159 | 0.490 |
Why?
|
| Escherichia coli Infections | 1 | 2015 | 39 | 0.490 |
Why?
|
| Pneumonia, Viral | 2 | 2011 | 103 | 0.480 |
Why?
|
| Invasive Pulmonary Aspergillosis | 1 | 2014 | 1 | 0.480 |
Why?
|
| Cough | 1 | 2014 | 19 | 0.480 |
Why?
|
| Methotrexate | 4 | 2015 | 64 | 0.470 |
Why?
|
| Retinitis | 2 | 2005 | 3 | 0.470 |
Why?
|
| Travel | 3 | 2009 | 15 | 0.460 |
Why?
|
| Counseling | 4 | 2007 | 97 | 0.450 |
Why?
|
| Attitude to Health | 2 | 2015 | 166 | 0.450 |
Why?
|
| Edema | 2 | 2015 | 28 | 0.450 |
Why?
|
| Drug Resistance, Viral | 2 | 2011 | 9 | 0.450 |
Why?
|
| Diabetes Mellitus | 1 | 2017 | 412 | 0.440 |
Why?
|
| Glucose Oxidase | 1 | 2013 | 1 | 0.440 |
Why?
|
| Lactoperoxidase | 1 | 2013 | 1 | 0.440 |
Why?
|
| Pneumonia, Ventilator-Associated | 1 | 2013 | 8 | 0.440 |
Why?
|
| Muramidase | 1 | 2013 | 8 | 0.440 |
Why?
|
| Acquired Immunodeficiency Syndrome | 2 | 2003 | 16 | 0.440 |
Why?
|
| Oral Hygiene | 1 | 2013 | 16 | 0.440 |
Why?
|
| Rocky Mountain Spotted Fever | 1 | 2013 | 8 | 0.440 |
Why?
|
| Lymphohistiocytosis, Hemophagocytic | 2 | 2018 | 9 | 0.430 |
Why?
|
| Intracranial Hypertension | 1 | 2013 | 19 | 0.430 |
Why?
|
| Parotitis | 1 | 2012 | 2 | 0.430 |
Why?
|
| Conjunctivitis | 1 | 2012 | 3 | 0.430 |
Why?
|
| Mycoplasma pneumoniae | 1 | 2012 | 4 | 0.430 |
Why?
|
| Pneumonia, Mycoplasma | 1 | 2012 | 4 | 0.420 |
Why?
|
| Fatal Outcome | 7 | 2018 | 83 | 0.420 |
Why?
|
| Mucositis | 1 | 2012 | 8 | 0.420 |
Why?
|
| Drug Therapy, Combination | 5 | 2019 | 288 | 0.420 |
Why?
|
| Preventive Health Services | 1 | 2013 | 44 | 0.420 |
Why?
|
| Socioeconomic Factors | 7 | 2020 | 429 | 0.420 |
Why?
|
| Kidney Diseases | 1 | 2015 | 249 | 0.410 |
Why?
|
| Streptococcal Infections | 2 | 2010 | 22 | 0.410 |
Why?
|
| Neuraminidase | 1 | 2012 | 10 | 0.400 |
Why?
|
| Viral Proteins | 1 | 2012 | 35 | 0.400 |
Why?
|
| Arthritis | 3 | 2015 | 39 | 0.400 |
Why?
|
| Diarrhea, Infantile | 2 | 2009 | 5 | 0.400 |
Why?
|
| Purpura Fulminans | 1 | 2011 | 4 | 0.390 |
Why?
|
| Viral Load | 5 | 2013 | 70 | 0.390 |
Why?
|
| Orbital Cellulitis | 1 | 2011 | 1 | 0.380 |
Why?
|
| Risk Factors | 9 | 2018 | 3880 | 0.380 |
Why?
|
| Eye Infections, Bacterial | 1 | 2011 | 5 | 0.380 |
Why?
|
| Intention | 2 | 2022 | 31 | 0.380 |
Why?
|
| Oseltamivir | 1 | 2011 | 5 | 0.380 |
Why?
|
| Vasculitis | 3 | 2003 | 24 | 0.380 |
Why?
|
| Developing Countries | 4 | 2013 | 48 | 0.370 |
Why?
|
| World Health Organization | 3 | 2017 | 15 | 0.360 |
Why?
|
| Prognosis | 7 | 2018 | 1496 | 0.360 |
Why?
|
| Pharyngitis | 1 | 2010 | 10 | 0.360 |
Why?
|
| Risk Assessment | 6 | 2019 | 1427 | 0.360 |
Why?
|
| Mastitis | 4 | 2013 | 4 | 0.360 |
Why?
|
| Jugular Veins | 1 | 2010 | 26 | 0.350 |
Why?
|
| Dengue | 1 | 2009 | 5 | 0.350 |
Why?
|
| Venous Thrombosis | 1 | 2010 | 49 | 0.350 |
Why?
|
| Interview, Psychological | 1 | 2009 | 10 | 0.340 |
Why?
|
| Mothers | 4 | 2013 | 88 | 0.340 |
Why?
|
| Pyomyositis | 1 | 2009 | 2 | 0.340 |
Why?
|
| Entamoebiasis | 1 | 2009 | 1 | 0.330 |
Why?
|
| Liver Abscess | 1 | 2009 | 2 | 0.330 |
Why?
|
| Anemia, Aplastic | 1 | 2009 | 5 | 0.330 |
Why?
|
| Odds Ratio | 3 | 2020 | 472 | 0.330 |
Why?
|
| Treatment Outcome | 11 | 2015 | 3304 | 0.330 |
Why?
|
| Platelet Transfusion | 1 | 2009 | 16 | 0.330 |
Why?
|
| Gram-Negative Bacterial Infections | 2 | 2006 | 14 | 0.330 |
Why?
|
| Streptococcus pneumoniae | 1 | 2009 | 40 | 0.330 |
Why?
|
| Pharyngeal Diseases | 1 | 2009 | 9 | 0.330 |
Why?
|
| Abdominal Pain | 1 | 2009 | 44 | 0.320 |
Why?
|
| Acute Lung Injury | 1 | 2009 | 33 | 0.320 |
Why?
|
| Antirheumatic Agents | 2 | 1999 | 29 | 0.320 |
Why?
|
| Pneumonia | 2 | 1999 | 67 | 0.320 |
Why?
|
| Herpes Simplex | 1 | 2008 | 13 | 0.310 |
Why?
|
| Liver Failure, Acute | 1 | 2008 | 10 | 0.310 |
Why?
|
| Ustilaginales | 1 | 2008 | 3 | 0.310 |
Why?
|
| Fungemia | 1 | 2008 | 3 | 0.310 |
Why?
|
| Short Bowel Syndrome | 1 | 2008 | 12 | 0.310 |
Why?
|
| Anemia, Sickle Cell | 2 | 1998 | 45 | 0.310 |
Why?
|
| Lupus Erythematosus, Systemic | 3 | 2000 | 148 | 0.300 |
Why?
|
| Microbial Sensitivity Tests | 4 | 2015 | 80 | 0.300 |
Why?
|
| Sinusitis | 2 | 2006 | 17 | 0.290 |
Why?
|
| Catheterization, Central Venous | 1 | 2008 | 62 | 0.290 |
Why?
|
| Retrospective Studies | 8 | 2018 | 3505 | 0.290 |
Why?
|
| Malaria | 1 | 2006 | 11 | 0.280 |
Why?
|
| Malaria, Falciparum | 2 | 1999 | 3 | 0.280 |
Why?
|
| AIDS Serodiagnosis | 2 | 2006 | 4 | 0.280 |
Why?
|
| Orbital Diseases | 1 | 2006 | 7 | 0.280 |
Why?
|
| Cellulitis | 1 | 2006 | 10 | 0.270 |
Why?
|
| Influenza A Virus, H3N2 Subtype | 1 | 2006 | 23 | 0.270 |
Why?
|
| Methylobacteriaceae | 1 | 2006 | 2 | 0.270 |
Why?
|
| Anti-Inflammatory Agents | 4 | 2009 | 99 | 0.270 |
Why?
|
| Neuroblastoma | 1 | 2006 | 31 | 0.270 |
Why?
|
| Catheterization | 1 | 2006 | 58 | 0.260 |
Why?
|
| Cohort Studies | 4 | 2019 | 1816 | 0.260 |
Why?
|
| Leukemia, T-Cell | 1 | 2005 | 2 | 0.260 |
Why?
|
| Postoperative Complications | 1 | 2011 | 780 | 0.260 |
Why?
|
| Chickenpox | 1 | 2005 | 4 | 0.260 |
Why?
|
| Glucocorticoids | 2 | 2004 | 145 | 0.260 |
Why?
|
| Meningoencephalitis | 2 | 2002 | 4 | 0.250 |
Why?
|
| Time Factors | 6 | 2018 | 2145 | 0.250 |
Why?
|
| Probiotics | 1 | 2005 | 10 | 0.250 |
Why?
|
| Lactobacillus | 1 | 2005 | 14 | 0.250 |
Why?
|
| Africa South of the Sahara | 3 | 2013 | 21 | 0.240 |
Why?
|
| Mental Disorders | 1 | 2005 | 123 | 0.240 |
Why?
|
| Psychotherapy, Group | 2 | 2014 | 17 | 0.240 |
Why?
|
| Cavernous Sinus Thrombosis | 1 | 2004 | 2 | 0.230 |
Why?
|
| Age Factors | 4 | 2018 | 1187 | 0.230 |
Why?
|
| Fluorescent Antibody Technique, Direct | 1 | 2003 | 2 | 0.230 |
Why?
|
| Respiratory Syncytial Viruses | 1 | 2003 | 7 | 0.230 |
Why?
|
| Respiratory Syncytial Virus Infections | 1 | 2003 | 10 | 0.230 |
Why?
|
| Meningitis, Viral | 1 | 2003 | 1 | 0.230 |
Why?
|
| Enterovirus B, Human | 1 | 2003 | 1 | 0.230 |
Why?
|
| Coxsackievirus Infections | 1 | 2003 | 2 | 0.230 |
Why?
|
| Encephalitis, Viral | 1 | 2003 | 4 | 0.230 |
Why?
|
| Cerebral Ventricles | 1 | 2003 | 11 | 0.220 |
Why?
|
| Bacterial Infections | 2 | 2001 | 51 | 0.220 |
Why?
|
| Post-Exposure Prophylaxis | 2 | 2013 | 4 | 0.220 |
Why?
|
| Animals | 6 | 2017 | 7510 | 0.220 |
Why?
|
| Primary Prevention | 1 | 2003 | 54 | 0.220 |
Why?
|
| DNA, Viral | 4 | 2018 | 54 | 0.210 |
Why?
|
| Poliovirus Vaccine, Oral | 2 | 2013 | 3 | 0.210 |
Why?
|
| Mumps | 1 | 2002 | 2 | 0.210 |
Why?
|
| Severity of Illness Index | 4 | 2014 | 881 | 0.210 |
Why?
|
| Angiolymphoid Hyperplasia with Eosinophilia | 1 | 2002 | 3 | 0.210 |
Why?
|
| Lymphadenitis | 2 | 2015 | 3 | 0.210 |
Why?
|
| Penicillins | 2 | 2001 | 11 | 0.210 |
Why?
|
| Meningitis, Bacterial | 1 | 2001 | 5 | 0.200 |
Why?
|
| Crohn Disease | 2 | 1999 | 26 | 0.200 |
Why?
|
| Drug Administration Schedule | 4 | 2013 | 276 | 0.200 |
Why?
|
| Immunoglobulins, Intravenous | 3 | 2009 | 23 | 0.190 |
Why?
|
| Medication Adherence | 1 | 2013 | 161 | 0.190 |
Why?
|
| Bacteriological Techniques | 1 | 2001 | 16 | 0.190 |
Why?
|
| Laryngoscopy | 1 | 2021 | 41 | 0.190 |
Why?
|
| Costa Rica | 1 | 2020 | 1 | 0.190 |
Why?
|
| Suburban Population | 1 | 2020 | 5 | 0.190 |
Why?
|
| Deglutition Disorders | 1 | 2021 | 51 | 0.180 |
Why?
|
| Viral Vaccines | 1 | 2020 | 11 | 0.180 |
Why?
|
| Disease Progression | 2 | 2018 | 594 | 0.180 |
Why?
|
| Nephrotic Syndrome | 2 | 1999 | 13 | 0.180 |
Why?
|
| Purpura, Schoenlein-Henoch | 1 | 2000 | 3 | 0.180 |
Why?
|
| Clindamycin | 2 | 2011 | 22 | 0.180 |
Why?
|
| Lymphocytes | 2 | 2014 | 57 | 0.180 |
Why?
|
| China | 1 | 2020 | 50 | 0.180 |
Why?
|
| Postpartum Period | 2 | 2014 | 33 | 0.180 |
Why?
|
| Rett Syndrome | 1 | 2000 | 1 | 0.180 |
Why?
|
| Virus Shedding | 2 | 2013 | 5 | 0.180 |
Why?
|
| Sexual Partners | 1 | 2020 | 35 | 0.180 |
Why?
|
| Tracheoesophageal Fistula | 1 | 2000 | 5 | 0.180 |
Why?
|
| Adenovirus Infections, Human | 1 | 2000 | 6 | 0.180 |
Why?
|
| Acyl-CoA Dehydrogenases | 1 | 1999 | 2 | 0.180 |
Why?
|
| Lipid Metabolism, Inborn Errors | 1 | 1999 | 3 | 0.180 |
Why?
|
| Ribavirin | 1 | 2000 | 28 | 0.170 |
Why?
|
| Nocardia Infections | 1 | 1999 | 2 | 0.170 |
Why?
|
| Fibrosarcoma | 1 | 1999 | 4 | 0.170 |
Why?
|
| Neutrophils | 2 | 2013 | 106 | 0.170 |
Why?
|
| Enterobacteriaceae | 1 | 2019 | 11 | 0.170 |
Why?
|
| Granulomatous Disease, Chronic | 1 | 1999 | 6 | 0.170 |
Why?
|
| Toxocariasis | 1 | 1999 | 1 | 0.170 |
Why?
|
| Toxocara canis | 1 | 1999 | 1 | 0.170 |
Why?
|
| Hepatitis | 1 | 1999 | 8 | 0.170 |
Why?
|
| Encephalocele | 1 | 1999 | 2 | 0.170 |
Why?
|
| Typhoid Fever | 1 | 1999 | 20 | 0.170 |
Why?
|
| Chronic Disease | 2 | 2014 | 406 | 0.170 |
Why?
|
| Iritis | 1 | 1999 | 1 | 0.170 |
Why?
|
| Injections, Intravenous | 3 | 2009 | 78 | 0.170 |
Why?
|
| Environmental Exposure | 1 | 2020 | 91 | 0.170 |
Why?
|
| Spinal Puncture | 1 | 1999 | 20 | 0.170 |
Why?
|
| Sensitivity and Specificity | 3 | 2009 | 581 | 0.170 |
Why?
|
| Methylprednisolone | 2 | 1999 | 12 | 0.170 |
Why?
|
| Pilot Projects | 3 | 2013 | 547 | 0.170 |
Why?
|
| Logistic Models | 3 | 2018 | 783 | 0.170 |
Why?
|
| Fatty Acids | 1 | 1999 | 98 | 0.160 |
Why?
|
| Liver Diseases | 1 | 1999 | 70 | 0.160 |
Why?
|
| Nutritional Status | 1 | 1999 | 75 | 0.160 |
Why?
|
| Rickets | 1 | 1998 | 2 | 0.160 |
Why?
|
| Internet | 1 | 2020 | 197 | 0.160 |
Why?
|
| Antacids | 1 | 1998 | 4 | 0.160 |
Why?
|
| Tuberculosis | 2 | 2014 | 15 | 0.160 |
Why?
|
| Linear Models | 1 | 2020 | 448 | 0.160 |
Why?
|
| Hypophosphatemia | 1 | 1998 | 5 | 0.160 |
Why?
|
| Prednisone | 2 | 2015 | 61 | 0.160 |
Why?
|
| Bronchoalveolar Lavage Fluid | 2 | 2014 | 59 | 0.160 |
Why?
|
| Hemoptysis | 1 | 1998 | 3 | 0.160 |
Why?
|
| Blastomycosis | 1 | 1998 | 3 | 0.160 |
Why?
|
| Child Abuse, Sexual | 1 | 1998 | 6 | 0.160 |
Why?
|
| Clostridium Infections | 1 | 1998 | 9 | 0.160 |
Why?
|
| Antisickling Agents | 1 | 1998 | 1 | 0.160 |
Why?
|
| Hydroxyurea | 1 | 1998 | 2 | 0.160 |
Why?
|
| Quinine | 2 | 1999 | 3 | 0.160 |
Why?
|
| Thoracic Diseases | 1 | 1998 | 4 | 0.160 |
Why?
|
| Urethral Diseases | 1 | 1998 | 18 | 0.160 |
Why?
|
| Hamartoma | 1 | 1998 | 10 | 0.160 |
Why?
|
| Professional Practice | 1 | 1998 | 24 | 0.160 |
Why?
|
| Lymphatic Diseases | 1 | 1998 | 10 | 0.160 |
Why?
|
| Prospective Studies | 5 | 2018 | 2282 | 0.160 |
Why?
|
| Takayasu Arteritis | 1 | 1998 | 1 | 0.160 |
Why?
|
| Africa | 4 | 2014 | 27 | 0.160 |
Why?
|
| Vascular Diseases | 1 | 1999 | 66 | 0.160 |
Why?
|
| Airway Obstruction | 1 | 1998 | 29 | 0.160 |
Why?
|
| Emergencies | 1 | 1998 | 47 | 0.150 |
Why?
|
| Louisiana | 4 | 2015 | 11 | 0.150 |
Why?
|
| Scurvy | 1 | 1998 | 3 | 0.150 |
Why?
|
| Craniosynostoses | 1 | 1998 | 62 | 0.150 |
Why?
|
| Death, Sudden, Cardiac | 1 | 2018 | 62 | 0.150 |
Why?
|
| Ribs | 1 | 1998 | 44 | 0.150 |
Why?
|
| Pruritus | 1 | 2018 | 47 | 0.150 |
Why?
|
| Gastritis | 1 | 1997 | 4 | 0.150 |
Why?
|
| Helicobacter pylori | 1 | 1997 | 8 | 0.150 |
Why?
|
| Helicobacter Infections | 1 | 1997 | 9 | 0.150 |
Why?
|
| Dermatitis | 1 | 1997 | 21 | 0.150 |
Why?
|
| Insect Vectors | 1 | 2017 | 4 | 0.150 |
Why?
|
| Age Distribution | 2 | 2013 | 206 | 0.150 |
Why?
|
| Vancomycin | 2 | 2011 | 22 | 0.150 |
Why?
|
| Guillain-Barre Syndrome | 1 | 2017 | 7 | 0.150 |
Why?
|
| Splenectomy | 1 | 2017 | 21 | 0.140 |
Why?
|
| Prion Diseases | 1 | 1997 | 3 | 0.140 |
Why?
|
| Familial Mediterranean Fever | 1 | 1996 | 2 | 0.140 |
Why?
|
| Aged | 4 | 2018 | 10308 | 0.140 |
Why?
|
| Human papillomavirus 18 | 1 | 2016 | 1 | 0.140 |
Why?
|
| Human papillomavirus 16 | 1 | 2016 | 3 | 0.140 |
Why?
|
| Magnetic Resonance Imaging | 4 | 2017 | 1325 | 0.140 |
Why?
|
| Prevalence | 3 | 2018 | 989 | 0.140 |
Why?
|
| Antibodies, Viral | 3 | 2013 | 58 | 0.140 |
Why?
|
| Child Mortality | 1 | 2016 | 3 | 0.130 |
Why?
|
| Maternal Mortality | 1 | 2016 | 12 | 0.130 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 1999 | 458 | 0.130 |
Why?
|
| Health Personnel | 1 | 2017 | 121 | 0.130 |
Why?
|
| Drug Administration Routes | 2 | 2012 | 12 | 0.130 |
Why?
|
| Infant Mortality | 1 | 2016 | 23 | 0.130 |
Why?
|
| Melioidosis | 1 | 2015 | 2 | 0.130 |
Why?
|
| Physician's Role | 1 | 2016 | 40 | 0.130 |
Why?
|
| Feasibility Studies | 2 | 2014 | 294 | 0.130 |
Why?
|
| Skin | 1 | 1997 | 211 | 0.130 |
Why?
|
| Immunoglobulin G | 2 | 2013 | 122 | 0.130 |
Why?
|
| Forehead | 1 | 2015 | 13 | 0.130 |
Why?
|
| beta-Lactamases | 1 | 2015 | 13 | 0.130 |
Why?
|
| Clinical Competence | 1 | 1998 | 331 | 0.130 |
Why?
|
| Uveitis | 1 | 2015 | 2 | 0.130 |
Why?
|
| Synovitis | 1 | 2015 | 6 | 0.120 |
Why?
|
| Escherichia coli | 1 | 2015 | 87 | 0.120 |
Why?
|
| Genotype | 1 | 2016 | 733 | 0.120 |
Why?
|
| Problem Solving | 1 | 2014 | 28 | 0.120 |
Why?
|
| Chemoprevention | 1 | 2014 | 11 | 0.120 |
Why?
|
| Perception | 1 | 2015 | 101 | 0.120 |
Why?
|
| Urban Health | 2 | 2011 | 15 | 0.120 |
Why?
|
| Social Support | 2 | 2007 | 182 | 0.120 |
Why?
|
| South Africa | 2 | 2013 | 11 | 0.120 |
Why?
|
| Meningococcal Infections | 1 | 2013 | 7 | 0.110 |
Why?
|
| Meningitis, Meningococcal | 1 | 2013 | 6 | 0.110 |
Why?
|
| Healthcare Disparities | 1 | 2016 | 169 | 0.110 |
Why?
|
| Monocytes | 1 | 2014 | 127 | 0.110 |
Why?
|
| Poliovirus | 1 | 2013 | 3 | 0.110 |
Why?
|
| North Carolina | 2 | 2009 | 1538 | 0.110 |
Why?
|
| Drug Resistance, Multiple, Viral | 1 | 2013 | 1 | 0.110 |
Why?
|
| Rickettsia rickettsii | 1 | 2013 | 3 | 0.110 |
Why?
|
| Palatine Tonsil | 1 | 2013 | 7 | 0.110 |
Why?
|
| Directive Counseling | 1 | 2013 | 18 | 0.110 |
Why?
|
| Length of Stay | 2 | 2013 | 312 | 0.110 |
Why?
|
| Drug Combinations | 1 | 2013 | 98 | 0.110 |
Why?
|
| Mouth Mucosa | 1 | 2013 | 30 | 0.110 |
Why?
|
| Parotid Gland | 1 | 2012 | 6 | 0.110 |
Why?
|
| Azithromycin | 1 | 2012 | 15 | 0.110 |
Why?
|
| Biopsy | 3 | 1998 | 259 | 0.100 |
Why?
|
| Administration, Topical | 1 | 2013 | 139 | 0.100 |
Why?
|
| Intestinal Mucosa | 1 | 2013 | 71 | 0.100 |
Why?
|
| Sex Distribution | 1 | 2013 | 191 | 0.100 |
Why?
|
| Lung | 1 | 2014 | 249 | 0.100 |
Why?
|
| Respiration, Artificial | 1 | 2013 | 98 | 0.100 |
Why?
|
| Vaginal Discharge | 1 | 2012 | 3 | 0.100 |
Why?
|
| Shigella flexneri | 1 | 2012 | 3 | 0.100 |
Why?
|
| Vaginosis, Bacterial | 1 | 2012 | 7 | 0.100 |
Why?
|
| Dysentery, Bacillary | 1 | 2012 | 12 | 0.100 |
Why?
|
| Cost-Benefit Analysis | 1 | 2013 | 185 | 0.100 |
Why?
|
| Syndrome | 2 | 2010 | 72 | 0.100 |
Why?
|
| Poliomyelitis | 1 | 2012 | 4 | 0.100 |
Why?
|
| Drug Dosage Calculations | 1 | 2012 | 6 | 0.100 |
Why?
|
| Ferrets | 1 | 2012 | 20 | 0.100 |
Why?
|
| Neutropenia | 1 | 2012 | 29 | 0.100 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2012 | 30 | 0.100 |
Why?
|
| Molecular Structure | 1 | 2012 | 59 | 0.100 |
Why?
|
| HIV Seropositivity | 1 | 2012 | 14 | 0.100 |
Why?
|
| Multivariate Analysis | 2 | 2011 | 684 | 0.100 |
Why?
|
| Brain | 1 | 1999 | 948 | 0.100 |
Why?
|
| Double-Blind Method | 3 | 2014 | 525 | 0.100 |
Why?
|
| Drug Design | 1 | 2012 | 43 | 0.100 |
Why?
|
| RNA, Viral | 5 | 2013 | 48 | 0.100 |
Why?
|
| Anemia | 1 | 2012 | 58 | 0.100 |
Why?
|
| Safety | 2 | 2003 | 77 | 0.100 |
Why?
|
| Immunologic Tests | 1 | 2011 | 4 | 0.100 |
Why?
|
| Gravidity | 1 | 2011 | 3 | 0.100 |
Why?
|
| Hematologic Tests | 1 | 2011 | 10 | 0.100 |
Why?
|
| Endemic Diseases | 2 | 2011 | 4 | 0.100 |
Why?
|
| Drugs, Investigational | 1 | 2011 | 6 | 0.100 |
Why?
|
| Central Nervous System | 2 | 2004 | 43 | 0.090 |
Why?
|
| Drainage | 1 | 2011 | 72 | 0.090 |
Why?
|
| Parity | 1 | 2010 | 20 | 0.090 |
Why?
|
| Diagnostic and Statistical Manual of Mental Disorders | 1 | 2010 | 27 | 0.090 |
Why?
|
| Patient Education as Topic | 1 | 2013 | 271 | 0.090 |
Why?
|
| Genes, env | 1 | 2010 | 1 | 0.090 |
Why?
|
| Doxycycline | 2 | 2002 | 26 | 0.090 |
Why?
|
| Monitoring, Physiologic | 1 | 2011 | 73 | 0.090 |
Why?
|
| Statistics, Nonparametric | 2 | 2011 | 129 | 0.090 |
Why?
|
| Chi-Square Distribution | 2 | 2011 | 297 | 0.090 |
Why?
|
| Ceftriaxone | 2 | 2001 | 14 | 0.090 |
Why?
|
| Dengue Virus | 1 | 2009 | 4 | 0.090 |
Why?
|
| Guatemala | 1 | 2009 | 10 | 0.090 |
Why?
|
| Cytomegalovirus Infections | 2 | 2008 | 48 | 0.090 |
Why?
|
| Interviews as Topic | 1 | 2010 | 266 | 0.080 |
Why?
|
| Cyclophosphamide | 3 | 2015 | 38 | 0.080 |
Why?
|
| Uganda | 2 | 2013 | 8 | 0.080 |
Why?
|
| Prednisolone | 2 | 1999 | 9 | 0.080 |
Why?
|
| Opportunistic Infections | 1 | 2009 | 17 | 0.080 |
Why?
|
| Causality | 2 | 2015 | 38 | 0.080 |
Why?
|
| Ambulatory Care Facilities | 2 | 2006 | 83 | 0.080 |
Why?
|
| Simplexvirus | 1 | 2008 | 3 | 0.080 |
Why?
|
| Aspirin | 1 | 2009 | 63 | 0.080 |
Why?
|
| Liver Transplantation | 2 | 2000 | 179 | 0.080 |
Why?
|
| Immunologic Factors | 1 | 2009 | 49 | 0.080 |
Why?
|
| Mycoses | 1 | 2008 | 20 | 0.080 |
Why?
|
| Adrenal Cortex Hormones | 2 | 2000 | 122 | 0.080 |
Why?
|
| Comorbidity | 1 | 2009 | 566 | 0.070 |
Why?
|
| Bone Marrow | 2 | 2006 | 70 | 0.070 |
Why?
|
| Mental Health Services | 1 | 2007 | 31 | 0.070 |
Why?
|
| Emergency Service, Hospital | 1 | 2011 | 467 | 0.070 |
Why?
|
| Disease Transmission, Infectious | 1 | 2007 | 17 | 0.070 |
Why?
|
| Reproducibility of Results | 1 | 2009 | 765 | 0.070 |
Why?
|
| Radiography | 2 | 1998 | 374 | 0.070 |
Why?
|
| Prenatal Diagnosis | 1 | 2006 | 24 | 0.070 |
Why?
|
| Lymphocyte Count | 1 | 2006 | 24 | 0.070 |
Why?
|
| Diagnostic Imaging | 1 | 2007 | 94 | 0.070 |
Why?
|
| Drug Monitoring | 1 | 2006 | 27 | 0.070 |
Why?
|
| Skin Ulcer | 1 | 2006 | 11 | 0.070 |
Why?
|
| Remission Induction | 1 | 2006 | 84 | 0.070 |
Why?
|
| Heart Arrest | 1 | 2006 | 38 | 0.070 |
Why?
|
| Kidney Transplantation | 1 | 2011 | 517 | 0.070 |
Why?
|
| Species Specificity | 1 | 2006 | 90 | 0.070 |
Why?
|
| Diet | 2 | 1999 | 390 | 0.070 |
Why?
|
| Seroepidemiologic Studies | 1 | 2005 | 10 | 0.070 |
Why?
|
| Incidence | 2 | 2000 | 1199 | 0.070 |
Why?
|
| Red Cross | 1 | 2005 | 2 | 0.070 |
Why?
|
| Pregnancy Trimester, Third | 1 | 2005 | 18 | 0.070 |
Why?
|
| Reverse Transcriptase Inhibitors | 1 | 2005 | 7 | 0.070 |
Why?
|
| Mice | 1 | 2012 | 2474 | 0.070 |
Why?
|
| Pleural Effusion | 1 | 2005 | 12 | 0.070 |
Why?
|
| Chickenpox Vaccine | 1 | 2005 | 3 | 0.060 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 2005 | 97 | 0.060 |
Why?
|
| Acyclovir | 1 | 2005 | 14 | 0.060 |
Why?
|
| Cost of Illness | 1 | 2005 | 70 | 0.060 |
Why?
|
| Administration, Oral | 2 | 2011 | 187 | 0.060 |
Why?
|
| Immunosuppressive Agents | 2 | 2004 | 240 | 0.060 |
Why?
|
| DNA Fingerprinting | 1 | 2005 | 6 | 0.060 |
Why?
|
| Mononuclear Phagocyte System | 1 | 2004 | 1 | 0.060 |
Why?
|
| Bacterial Typing Techniques | 1 | 2005 | 17 | 0.060 |
Why?
|
| Immune System | 1 | 2004 | 7 | 0.060 |
Why?
|
| Immunity, Cellular | 1 | 2004 | 20 | 0.060 |
Why?
|
| Gastrointestinal Tract | 1 | 2004 | 29 | 0.060 |
Why?
|
| Hemorrhage | 1 | 2005 | 100 | 0.060 |
Why?
|
| Musculoskeletal System | 1 | 2004 | 13 | 0.060 |
Why?
|
| Bone Diseases, Metabolic | 1 | 2004 | 23 | 0.060 |
Why?
|
| Combined Modality Therapy | 1 | 2006 | 560 | 0.060 |
Why?
|
| Diarrhea | 1 | 2005 | 60 | 0.060 |
Why?
|
| Gram-Positive Bacterial Infections | 1 | 2004 | 12 | 0.060 |
Why?
|
| Amitriptyline | 2 | 2014 | 6 | 0.060 |
Why?
|
| Referral and Consultation | 1 | 2005 | 142 | 0.060 |
Why?
|
| Leukocyte Count | 2 | 2014 | 49 | 0.060 |
Why?
|
| Bottle Feeding | 1 | 2004 | 1 | 0.060 |
Why?
|
| Viridans Streptococci | 1 | 2004 | 5 | 0.060 |
Why?
|
| Blindness | 1 | 2004 | 10 | 0.060 |
Why?
|
| Epidemiologic Research Design | 1 | 2003 | 5 | 0.060 |
Why?
|
| Metabolic Clearance Rate | 1 | 2003 | 17 | 0.060 |
Why?
|
| Maternal Age | 1 | 2003 | 15 | 0.060 |
Why?
|
| Tanzania | 1 | 2013 | 12 | 0.060 |
Why?
|
| Extracorporeal Membrane Oxygenation | 1 | 2004 | 25 | 0.060 |
Why?
|
| Methane | 1 | 2003 | 1 | 0.060 |
Why?
|
| Hydrogen | 1 | 2003 | 8 | 0.060 |
Why?
|
| Colic | 1 | 2003 | 3 | 0.060 |
Why?
|
| Colony Count, Microbial | 1 | 2003 | 18 | 0.060 |
Why?
|
| Respiratory Distress Syndrome, Adult | 1 | 2004 | 52 | 0.060 |
Why?
|
| United States | 3 | 2011 | 3975 | 0.060 |
Why?
|
| Culture Media | 1 | 2003 | 47 | 0.060 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2003 | 24 | 0.060 |
Why?
|
| Communicable Disease Control | 1 | 2003 | 15 | 0.060 |
Why?
|
| Probability | 1 | 2003 | 159 | 0.050 |
Why?
|
| Electroencephalography | 1 | 2003 | 72 | 0.050 |
Why?
|
| Colon | 1 | 2003 | 51 | 0.050 |
Why?
|
| Homeless Youth | 1 | 2003 | 1 | 0.050 |
Why?
|
| Nutrition Disorders | 1 | 2003 | 12 | 0.050 |
Why?
|
| Poverty | 1 | 2003 | 115 | 0.050 |
Why?
|
| Optic Nerve Diseases | 1 | 2002 | 19 | 0.050 |
Why?
|
| Asian Continental Ancestry Group | 1 | 2002 | 108 | 0.050 |
Why?
|
| Biopsy, Needle | 1 | 2002 | 93 | 0.050 |
Why?
|
| Lymph Node Excision | 1 | 2002 | 89 | 0.050 |
Why?
|
| Drug Resistance, Microbial | 1 | 2001 | 14 | 0.050 |
Why?
|
| Staining and Labeling | 1 | 2001 | 60 | 0.050 |
Why?
|
| Stevens-Johnson Syndrome | 1 | 2000 | 8 | 0.050 |
Why?
|
| Immunohistochemistry | 1 | 2002 | 534 | 0.050 |
Why?
|
| Reference Values | 2 | 2011 | 246 | 0.050 |
Why?
|
| Hospitalization | 1 | 2003 | 468 | 0.040 |
Why?
|
| California | 1 | 2000 | 63 | 0.040 |
Why?
|
| Sex Chromosome Aberrations | 1 | 2000 | 4 | 0.040 |
Why?
|
| X Chromosome | 1 | 2000 | 26 | 0.040 |
Why?
|
| Acyl-CoA Dehydrogenase | 1 | 1999 | 2 | 0.040 |
Why?
|
| Antibodies, Antinuclear | 1 | 2000 | 18 | 0.040 |
Why?
|
| Acidosis | 1 | 1999 | 18 | 0.040 |
Why?
|
| Nocardia asteroides | 1 | 1999 | 2 | 0.040 |
Why?
|
| Mesna | 1 | 1999 | 3 | 0.040 |
Why?
|
| Dactinomycin | 1 | 1999 | 10 | 0.040 |
Why?
|
| Adenoviruses, Human | 1 | 2000 | 28 | 0.040 |
Why?
|
| Ifosfamide | 1 | 1999 | 6 | 0.040 |
Why?
|
| Antibodies, Helminth | 1 | 1999 | 1 | 0.040 |
Why?
|
| Hepatic Encephalopathy | 1 | 1999 | 1 | 0.040 |
Why?
|
| Etoposide | 1 | 1999 | 34 | 0.040 |
Why?
|
| Nutritional Support | 1 | 1999 | 4 | 0.040 |
Why?
|
| Aspergillus fumigatus | 1 | 1999 | 4 | 0.040 |
Why?
|
| Autoimmune Diseases | 1 | 2000 | 48 | 0.040 |
Why?
|
| Polyradiculoneuropathy | 1 | 1999 | 1 | 0.040 |
Why?
|
| Aspergillosis | 1 | 1999 | 8 | 0.040 |
Why?
|
| Carboplatin | 1 | 1999 | 48 | 0.040 |
Why?
|
| Soft Tissue Infections | 1 | 1999 | 7 | 0.040 |
Why?
|
| Wound Infection | 1 | 1999 | 10 | 0.040 |
Why?
|
| Graves Disease | 1 | 1999 | 5 | 0.040 |
Why?
|
| Hypoglycemia | 1 | 1999 | 45 | 0.040 |
Why?
|
| Glomerulonephritis, Membranous | 1 | 1999 | 6 | 0.040 |
Why?
|
| Glasgow Coma Scale | 1 | 1999 | 27 | 0.040 |
Why?
|
| Intracranial Pressure | 1 | 1999 | 17 | 0.040 |
Why?
|
| Nutrition Assessment | 1 | 1999 | 55 | 0.040 |
Why?
|
| Bacteria | 1 | 2019 | 48 | 0.040 |
Why?
|
| Soft Tissue Neoplasms | 1 | 1999 | 39 | 0.040 |
Why?
|
| Doxorubicin | 1 | 1999 | 82 | 0.040 |
Why?
|
| Antimalarials | 1 | 1999 | 6 | 0.040 |
Why?
|
| Disease-Free Survival | 1 | 1999 | 317 | 0.040 |
Why?
|
| Phosphates | 1 | 1998 | 25 | 0.040 |
Why?
|
| Clostridium | 1 | 1998 | 4 | 0.040 |
Why?
|
| Prolapse | 1 | 1998 | 5 | 0.040 |
Why?
|
| Fecal Impaction | 1 | 1998 | 1 | 0.040 |
Why?
|
| Colostomy | 1 | 1998 | 4 | 0.040 |
Why?
|
| Anus Diseases | 1 | 1998 | 2 | 0.040 |
Why?
|
| Erythrocyte Indices | 1 | 1998 | 4 | 0.040 |
Why?
|
| Drug Evaluation | 1 | 1998 | 14 | 0.040 |
Why?
|
| Fetal Hemoglobin | 1 | 1998 | 4 | 0.040 |
Why?
|
| Metronidazole | 1 | 1998 | 15 | 0.040 |
Why?
|
| Radiography, Thoracic | 1 | 1998 | 45 | 0.040 |
Why?
|
| Hydroxychloroquine | 1 | 1998 | 11 | 0.040 |
Why?
|
| Diagnostic Errors | 1 | 1998 | 43 | 0.040 |
Why?
|
| Subclavian Artery | 1 | 1998 | 6 | 0.040 |
Why?
|
| Fecal Incontinence | 1 | 1998 | 23 | 0.040 |
Why?
|
| Enteral Nutrition | 1 | 1998 | 30 | 0.040 |
Why?
|
| Emergency Treatment | 1 | 1998 | 42 | 0.040 |
Why?
|
| Neck | 1 | 1998 | 27 | 0.040 |
Why?
|
| Anti-Infective Agents | 1 | 1998 | 44 | 0.040 |
Why?
|
| Ascorbic Acid | 1 | 1998 | 23 | 0.040 |
Why?
|
| Angiography | 1 | 1998 | 80 | 0.040 |
Why?
|
| Clostridium botulinum | 1 | 1997 | 3 | 0.040 |
Why?
|
| Phenotype | 1 | 2000 | 632 | 0.040 |
Why?
|
| Age of Onset | 1 | 1998 | 94 | 0.040 |
Why?
|
| Carotid Arteries | 1 | 1998 | 99 | 0.040 |
Why?
|
| Cephalosporins | 1 | 1997 | 9 | 0.040 |
Why?
|
| Botulism | 1 | 1997 | 9 | 0.040 |
Why?
|
| Gastroscopy | 1 | 1997 | 8 | 0.040 |
Why?
|
| Fever of Unknown Origin | 1 | 1997 | 10 | 0.040 |
Why?
|
| Recurrence | 1 | 1998 | 263 | 0.040 |
Why?
|
| Kuru | 1 | 1997 | 1 | 0.040 |
Why?
|
| Gerstmann-Straussler-Scheinker Disease | 1 | 1997 | 1 | 0.040 |
Why?
|
| Encephalopathy, Bovine Spongiform | 1 | 1997 | 2 | 0.040 |
Why?
|
| Creutzfeldt-Jakob Syndrome | 1 | 1997 | 5 | 0.040 |
Why?
|
| Mediterranean Region | 1 | 1996 | 1 | 0.040 |
Why?
|
| Middle East | 1 | 1996 | 5 | 0.040 |
Why?
|
| Accidents, Traffic | 1 | 1999 | 195 | 0.040 |
Why?
|
| Cattle | 1 | 1997 | 103 | 0.030 |
Why?
|
| Aortic Aneurysm, Abdominal | 1 | 1996 | 49 | 0.030 |
Why?
|
| Sociology | 1 | 2015 | 2 | 0.030 |
Why?
|
| Gene Expression Regulation | 1 | 1998 | 493 | 0.030 |
Why?
|
| Antidepressive Agents, Tricyclic | 1 | 2014 | 6 | 0.030 |
Why?
|
| Peer Group | 1 | 2014 | 44 | 0.030 |
Why?
|
| Placebos | 1 | 2014 | 63 | 0.030 |
Why?
|
| Antidepressive Agents | 1 | 2014 | 74 | 0.030 |
Why?
|
| Neisseria meningitidis | 1 | 2013 | 3 | 0.030 |
Why?
|
| Continental Population Groups | 1 | 2015 | 237 | 0.030 |
Why?
|
| Blood | 1 | 2013 | 14 | 0.030 |
Why?
|
| Feces | 1 | 2013 | 38 | 0.030 |
Why?
|
| Antibodies, Neutralizing | 1 | 2012 | 19 | 0.030 |
Why?
|
| Drug Eruptions | 1 | 2012 | 9 | 0.030 |
Why?
|
| Antiretroviral Therapy, Highly Active | 1 | 2011 | 29 | 0.020 |
Why?
|
| HIV Seronegativity | 1 | 2011 | 6 | 0.020 |
Why?
|
| Abortion, Spontaneous | 1 | 2011 | 12 | 0.020 |
Why?
|
| Blotting, Western | 1 | 2012 | 288 | 0.020 |
Why?
|
| Longitudinal Studies | 1 | 2013 | 770 | 0.020 |
Why?
|
| Viremia | 1 | 2010 | 5 | 0.020 |
Why?
|
| Pregnancy Outcome | 1 | 2011 | 90 | 0.020 |
Why?
|
| Phylogeny | 1 | 2010 | 56 | 0.020 |
Why?
|
| DNA Primers | 1 | 2010 | 91 | 0.020 |
Why?
|
| Virus Replication | 1 | 2010 | 42 | 0.020 |
Why?
|
| Critical Illness | 1 | 2011 | 88 | 0.020 |
Why?
|
| Base Sequence | 1 | 2010 | 252 | 0.020 |
Why?
|
| Molecular Sequence Data | 1 | 2010 | 357 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2011 | 483 | 0.020 |
Why?
|
| AIDS-Related Opportunistic Infections | 1 | 2008 | 9 | 0.020 |
Why?
|
| Herpesvirus 4, Human | 1 | 2008 | 9 | 0.020 |
Why?
|
| Epstein-Barr Virus Infections | 1 | 2008 | 10 | 0.020 |
Why?
|
| Cytomegalovirus | 1 | 2008 | 31 | 0.020 |
Why?
|
| Specimen Handling | 1 | 2008 | 32 | 0.020 |
Why?
|
| Cell Count | 1 | 2007 | 46 | 0.020 |
Why?
|
| Sodium | 1 | 2007 | 40 | 0.020 |
Why?
|
| Potassium | 1 | 2007 | 40 | 0.020 |
Why?
|
| Leukocytes | 1 | 2007 | 57 | 0.020 |
Why?
|
| Polymerase Chain Reaction | 1 | 2007 | 198 | 0.020 |
Why?
|
| Perineum | 1 | 2006 | 18 | 0.020 |
Why?
|
| Infant Nutrition Disorders | 1 | 2004 | 1 | 0.010 |
Why?
|
| Infant Food | 1 | 2004 | 3 | 0.010 |
Why?
|
| Gases | 1 | 2003 | 3 | 0.010 |
Why?
|
| Educational Status | 1 | 2004 | 181 | 0.010 |
Why?
|
| Feeding Behavior | 1 | 2004 | 161 | 0.010 |
Why?
|
| Decision Making | 1 | 2004 | 194 | 0.010 |
Why?
|
| Immunocompetence | 1 | 1999 | 11 | 0.010 |
Why?
|
| Musculoskeletal Diseases | 1 | 2000 | 37 | 0.010 |
Why?
|
| Kidney Glomerulus | 1 | 1999 | 30 | 0.010 |
Why?
|